Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ARTEMIS: A phase 2 trial of palupiprant (AN0025) with chemoradiotherapy and radiotherapy for the treatment of rectal cancer

Next Previous
Trial Profile

ARTEMIS: A phase 2 trial of palupiprant (AN0025) with chemoradiotherapy and radiotherapy for the treatment of rectal cancer

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Aug 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Palupiprant (Primary)
  • Indications Rectal cancer
  • Focus Therapeutic Use
  • Acronyms ARTEMIS

Most Recent Events

  • 14 Aug 2026 According to an Adlai Nortye media release, futility analysis of phase II study was successfully passed in March 2026, and the topline results are expected in the first half of 2027.
  • 14 Aug 2026 According to an Adlai Nortye media release, trial has completed enrollment and patient follow-up is ongoing.
  • 14 Aug 2026 Status changed to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top